Use of telaprevir in real clinical practice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Telaprevir is the first direct antiviral drug registered in the Russian Federation to treat patients with chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1. Phase III trials suggest that the inclusion of telaprevir into a therapy regimen considerably increases therapeutic efficiency. The results of its use in real clinical practice in patients with marked fibrosis and compensated liver cirrhosis also show a high sustained virological response rate; however, the slightly higher rate of adverse events is noted among patients with liver cirrhosis. The paper reviews the data available in the literature on the optimization of using telaprevir as part of triple antiviral therapy for chronic hepatitis C in HCV genotype 1 infection in real clinical practice.

Full Text

Restricted Access

About the authors

T. M Ignatova

Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University

Email: tmignatova@gmail.com

References

  1. Jacobson I.M., McHutchison J.G., Dusheiko G.M., Di Bisceglie A.M., Reddy K.R., Bzowej N.H. et al. ADVANCE study team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
  2. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S. et al. REALIZE study team. Telaprevir for retreatment of HCV-infection. N. Engl. J. Med. 2011; 364: 2417-2428.
  3. Sherman K.E., Flamm S.L., Afdhal N.H., Nelson D.R., Sulkowski M.S., Everson G.T et al. ILLUMINATE study team. Response-Guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
  4. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Intern. 2012; 32(Suppl. 1): 32-38.
  5. Игнатова Т.М. Телапревир в лечении хронического гепатита С: вопросы безопасности. Рос. журн. гастро-энтерол. гепатол. колопроктол. 2012; 22(4): 47-57.
  6. Гармаш И.В., Аришева О.С., Халилулин Т.П. Телапревир: место в современной противовирусной терапии хронического гепатита С и лекарственные взаимодействия. Клин. фармакол. тер. 2012; 21(2): 15-20.
  7. Краткая характеристика препарата ТЕЛАПРЕВИР, предназначенная для ЕС. http://www.ema.europa.eu
  8. Ghany M., Nelson D., Strader D., Thomas D.L., Seeff L.B.; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection. Hepatology 2011; 54 (4): 1433-1444.
  9. Leroy V., Serfaty L., Bourliere M., Bronowicki J-P., Delasalle P., Pariente A. et al. Protease ingibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the study of the Liver. Liver Intern. 2012; 32: 1477-1492.
  10. Asselah T., Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Intern. 2013; 33 (Suppl. 1): 93-104.
  11. Petta S., Craxi A. How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Intern. 2013; 33 (Suppl. 1): 23-29.
  12. Thompson A.J., Muir A.J., Sulkowski M.S., Patel K., Tillman H.L., Clark P.J. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
  13. Camma C., Petta S., Enea M., Bruno R., Bronte F., Capursi V. et al.; WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-860.
  14. Barritt A.S., Fried M.W. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142: 1314-1323.
  15. Esteban R., Buti M. Triple therapy with boceprevir or telaprevir for treatment naive HCV patients. Best Pract. Res. Clin. Gastroenterol. 2012; 26: 445-453.
  16. Asselah T. Triple therapy with boceprevir or telapre-vir for prior HCV non-responders. Best Pract. Res. Clin. Gastroenterol. 2012; 26: 455-462.
  17. Petta S., Craxi A. Terapeutic algoritms for chronic hepatitis C in the DDA era during the current economic crisis: whom to treat? how to treat? when to treat? BMC Infect. Dis. 2012; 12 (Suppl. 2): S3.
  18. Shiffman M.L., Benhamou Y. Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Liver Intern. 2013; 33 (Suppl. 1): 105-110
  19. Игнатова Т.М. Новые перспективы в лечении компенсированного цирроза печени, обусловленного вирусом гепатита С. Инфекционные болезни 2012; 10 (4): 49-59.
  20. Bourliere M., Wendt A., Fontaine H., Hezode C., Pol S., Bronowicki J.P. et al. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Intern. 2013; 33 (Suppl. 1): 46-55.
  21. Sulkowski M.S. Current management of hepatitis C virus infection in patients with HIV co-infection. J. Infect. Dis. 2013; 207 (Suppl. 1): 26-32.
  22. Joshi D., Carey I., Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C infection in liver transplant candidates and recipients. Aliment. Pharmacol. Ther. 2013; 37: 659-671.
  23. Kiser J.J., Burton J.R, Anderson P.L., Everson G T. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-1628.
  24. Hezode C., Fontaine H., Dorival C., Zoulim F., Larrey D., Canva V. et al. Effectiveness of Telaprevir or Boceprevir in Treatment-experienced Patients with HCV Genotype 1 Infection and Cirrhosis. In Press Accepted Manuscript in Gastroeneterology. http:// www.gastrojournal.org/article/ S0016-5085(14)00449-1.pdf.
  25. Pol S., Roberts S.K., Andreone P., Younossi Z., Diago M., Lawitz E.J. et al. Efficacy and safety of telaprevir-based regimen in cirrhotic patients with HCV genotype-1 and prior peginterferon/ ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology 2011; 54(Suppl.): аbstract 374.
  26. Ferreira P.R.A., Colombo M., Urbanek P., Strasser S.I., Moreno C., Fernandez I. et al. Treatment of Hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: efficacy results to week 16 on 1587 patients from the international telaprevir Early Access Program. Hepatology 2013; 58(Suppl.1): abstract 1873.
  27. Di Bisceglie A., Kuo A., Rustgi V.K., Sulkowski M.S., Stewart T.G., Fenkel J.M. et al. Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET). Hepatology 2013; 58(Suppl.1): abstract 41.
  28. Janczewska E., Flisiak R., Berak H., Zarebska-Michaluk D., Dobracka B., Pisula A. et al. Ribavirin dose reduction during Telaprevir containing triple therapy does not affect early viro-logic response in non-responders and relapsers with advanced liver fibrosis. J. Hepatol. 2013; 58(Suppl.): S334-S335.
  29. Berg T., Buggisch P., Hueppe D., Mauss S., Wedemeyer H., Hinrichsen H. et al. Real-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C GT1 in Germany - a 48 week interim analysis. Hepatology 2013; 58(Suppl.1): abstract 1900.
  30. Mauss S., Schober A., John C., Lutz T., Moog G., Bruch H.-R. et al. Safety and efficacy of triple therapy containing boceprevir (BOC) or telaprevir (TVR) plus peginterferon alfa-2a/ribavirin in patients with advanced fibrosis or cirrhosis in reallife setting. Hepatology 2013; 58 (Suppl. 1): abstract 1856.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies